An announcement from Zevra Therapeutics ( (ZVRA)) is now available. Zevra Therapeutics has announced the commercial availability of MIPLYFFA™ (arimoclomol), the first FDA-approved treatment for ...

Shares of NASDAQ ZVRA opened at $8.11 on Wednesday. Zevra Therapeutics has a 1 year low of $4.20 and a 1 year high of $9.76. The company has a market capitalization of $432.88 million, a price-to ...

Cantor Fitzgerald assumed coverage of Zevra Therapeutics (ZVRA) with an Overweight rating and $25 price target Zevra is a rare disease, ...

Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same period in the previous year, the business earned ($0.40) earnings per share.

With the business potentially at an important milestone, we thought we'd take a closer look at Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) future prospects. Zevra Therapeutics, Inc. discovers and ...

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying ...

Zevra Therapeutics (NASDAQ:ZVRA) is scheduled to announce Q3 earnings results on Tuesday, November 12th, after market close.The consensus EPS Estimate is -$0.41 (-2.5% Y/Y) and the consensus ...

Zevra Therapeutics (ZVRA – Research Report) received a Buy rating and a price target from Cantor Fitzgerald analyst Kristen Kluska today. The company’s shares closed yesterday at $8.24.

CELEBRATION, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment ...

View Zevra Therapeutics, Inc. (ZVRA) current and estimated P/E ratio data provided by Seeking Alpha.

Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced that Neil F.

Cantor Fitzgerald assumed coverage of Zevra Therapeutics (ZVRA) with an Overweight rating and $25 price target Zevra is a rare disease, commercial-stage biotechnology company with two approved ...